Recent Press Releases

Lilly, Zymeworks Announce Expansion of Strategic Licensing and Collaboration Agreement

Broad Bi-Specific Antibody Collaboration Now Includes Targets that Could Lead to New Cancer Immunotherapies

INDIANAPOLIS and

Abbott Reports Third-Quarter 2014 Results

- Third-Quarter Adjusted EPS Above Previous Guidance Range, Including Results From Discontinued Operations Related to Mylan Transaction -

ABBOTT PARK, Ill.,

GSK CEO and CFO Interviewed on 2014 Q3 Results

LONDON, October 22, 2014 /PRNewswire/ --

BIOGEN IDEC THIRD QUARTER 2014 REVENUES INCREASE 37% TO $2.5 BILLION

BIOGEN IDEC THIRD QUARTER 2014 REVENUES INCREASE 37% TO $2.5 BILLION PLEGRIDYTM Approved in the US and EU for Multiple Sclerosis ELOCTATETM Launched in the US for Hemophilia A Rollout of...

Roche invests for the future in its Basel site

Roche invests for the future in its Basel site Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development Today Roche presented...

U.S. Food and Drug Administration accepts filing of new drug application for empagliflozin/metformin fixed-dose combination

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 /PRNewswire/ -- The U.S.

Amgen Statement Regarding Third Point Investment

THOUSAND OAKS, Calif., Oct.

FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration's Pulmonary Allergy Drugs Advisory Committee (PADAC) voted...

ACTELION DELIVERS STRONG NINE MONTHS RESULTS

ACTELION DELIVERS STRONG NINE MONTHS RESULTS ALLSCHWIL/BASEL, SWITZERLAND - 21 October 2014 - Actelion Ltd (SIX: ATLN) today announced its results for the first nine months of 2014. PRODUCT...

ABBVIE ANNOUNCES NEW $5 BILLION STOCK REPURCHASE PROGRAM AND INCREASES DIVIDEND

ABBVIE ANNOUNCES NEW $5 BILLION STOCK REPURCHASE PROGRAM AND INCREASES DIVIDEND NORTH CHICAGO, Ill., Oct. 20, 2014 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today authorized...

Shire plc: AbbVie Terminates Offer for Shire

Shire plc: AbbVie Terminates Offer for Shire NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE...

Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, October 20, 2014

Lilly Declares Fourth-Quarter 2014 Dividend

INDIANAPOLIS, Oct.

Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma

Editor Note: For more information about this release, please scroll to bottom.

LONDON, October 20, 2014

ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S.

Positive Action Southern Initiative Commitment Continues with New Grants Awarded to Seven Organizations, Bringing Total Funding for Grassroots Projects to More than 2.8 Million to Date

New Large-Scale Study Will Look at How Nutrition Can Help Keep Patients from Returning to the Hospital

Advocate Health Care and Abbott Will Conduct Study on 3,000 Adult Patients to Quantify the Effectiveness of Nutrition Care in Hospital Settings

ABBOTT PARK, Ill.,

EPILEPSY PATIENT ADVOCACY GROUPS URGE PASSAGE OF DEA SCHEDULING LEGISLATION

EPILEPSY PATIENT ADVOCACY GROUPS URGE PASSAGE OF DEA SCHEDULING LEGISLATION WASHINGTON – A group of 15 epilepsy patient organizations sent a letter to congressional leaders urging them to pass...